A case of the blue blues: the safety issue of recognizing and avoiding the retinal toxicity of methylene blue compared to brilliant blue and trypan blue (2025)

Peer-Reviewed Study · Zafar S, Pulido JS, Patel SN, Yonekawa Y, Deaner JD · December 5, 2025

Zafar S et al., 2025-12-05: Case report of profound vision loss from methylene blue injected into the vitreous cavity in place of the intended surgical dye, with a safety argument for standardisation and safer packaging.

We reported a case of inner retinal toxicity from injection of methylene blue into the vitreous cavity resulting in profound vision loss.

Zafar S et al., 2025-12-05: Case report of profound vision loss from methylene blue injected into the vitreous cavity in place of the intended surgical dye, with a safety argument for standardisation and safer packaging. C5 (site-specific toxicity) and C8 (product/medication-error quality problem). Dose/route: intravitreal methylene blue given in error (concentration not in abstract); no light dose. Funder/conflicts not stated in abstract. Comparator: trypan blue and brilliant blue as the intended dyes. This is an error-of-product-identity harm rather than a dose escalation, and is recorded as such. Study type: case report.